back to US directory
us clinical guidance

Genital herpes diagnosis, treatment and counseling

CDC-aligned lesion testing, first-episode and recurrent treatment decisions, transmission counseling and pregnancy safety.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adolescents and adults with suspected or confirmed genital HSV-1 or HSV-2 infection. This page distinguishes a first clinical episode, episodic treatment, suppression and asymptomatic serology. Neonatal herpes, encephalitis, disseminated infection, severe immunocompromise and detailed obstetric delivery planning require specialist pathways.
sources for this section:CDC STI 2021

The Bottom Line

  • When genital lesions are present, confirm HSV with type-specific nucleic-acid amplification or culture from the lesion because clinical appearance alone is unreliable and HSV type informs recurrence counseling.
  • Treat every first clinical episode with systemic antiviral therapy even when initial manifestations appear mild; topical antiviral therapy offers little benefit and is discouraged.
  • Discuss episodic and daily suppressive therapy for recurrent symptomatic HSV-2 according to recurrence burden, transmission goals, psychosocial effect and patient preference; start episodic treatment promptly at prodrome or lesion onset.
  • Explain lifelong latency, possible asymptomatic shedding, lower recurrence and shedding with genital HSV-1 than HSV-2, condom risk reduction and avoidance of sex when lesions or prodrome are present.
sources for this section:CDC STI 2021

Practical clinical workflow

1
Take a nonjudgmental history of symptom onset, prior episodes, sexual sites and partners, pregnancy possibility, immune status, neurologic or urinary symptoms and medicines; examine all involved skin and mucosa.
2
Swab a fresh lesion for type-specific testing, offer HIV and other STI testing according to exposure, and use type-specific serology only for a CDC-supported question with confirmatory testing when needed.
3
Select acyclovir, valacyclovir or famciclovir under the CDC regimen and adjust for kidney function and interactions; offer analgesia, local care and a follow-up discussion after the acute distress settles.
4
Review recurrence frequency and treatment goals periodically, invite partner discussion and ensure pregnant patients inform both obstetric and newborn-care teams of genital herpes history.
sources for this section:CDC STI 2021

Safety boundaries and escalation

  • Severe headache, meningism, altered mental status, radicular pain, urinary retention, hepatitis, disseminated lesions or systemic illness requires urgent evaluation for complicated HSV and possible intravenous treatment.
  • New genital herpes late in pregnancy carries important neonatal risk and requires urgent obstetric and infectious-disease coordination; routine recurrent-disease advice is insufficient.
  • A painful genital ulcer has a broad differential, including syphilis and chancroid; obtain appropriate testing and do not let a presumed herpes diagnosis miss another treatable infection.
  • Do not prescribe antiviral therapy to an asymptomatic HSV-2-seropositive person solely to prevent recurrences that have never occurred; provide education and individualize substantial psychosocial distress.
sources for this section:CDC STI 2021

Localization

CDC STI Treatment Guidelines remain the principal US source, with state partner-services, testing and reporting requirements layered on top. Product labeling, pregnancy care and renal adjustment require current US references.
sources for this section:CDC STI 2021

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionSexually Transmitted Infections Treatment Guidelines, 2021: Genital HerpesMMWR 70(4); DOI 10.15585/mmwr.rr7004a1 路 published 2021-07-23 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.